HIV and atherosclerosis: moving from associations to mechanisms and interventions.

Distinct gender differences in anthropometric profiles of a peri-urban South African HIV population: a cross sectional study. BMC Infect Dis (2015) 0.75

The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes Mellitus. PLoS One (2015) 0.75

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. J Int AIDS Soc (2016) 0.75

Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls. PLoS One (2017) 0.75

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr (2004) 4.88

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation (2007) 4.66

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation (2011) 4.65

Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA (2009) 3.83

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65

Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2009) 3.52

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15

Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14

Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis (2003) 3.07

Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation (2007) 2.82

Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med (2005) 2.80

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67

Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis (2012) 2.64

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64

AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol (2011) 2.45

Does detection of carotid plaque affect physician behavior or motivate patients? Am Heart J (2007) 2.33

Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol (2012) 2.23

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17

Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2004) 2.17

Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98

Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol (2010) 1.61

Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis (2004) 1.54

Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol (2005) 1.50

Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. Am Heart J (2011) 1.50

Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr (2008) 1.46

Cardiovascular risks of antiretroviral therapy. N Engl J Med (2007) 1.45

Advanced lipoprotein testing does not improve identification of subclinical atherosclerosis in young adults: the Bogalusa Heart Study. Ann Intern Med (2005) 1.44

A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One (2012) 1.44

Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A (2011) 1.42

Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation (2007) 1.40

Predictors of carotid intima-media thickness progression in young adults: the Bogalusa Heart Study. Stroke (2007) 1.38

Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS (2012) 1.35

25-Hydroxyvitamin D and parathyroid hormone are not associated with carotid intima-media thickness or plaque in the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 1.33

Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol (2006) 1.29

Mönckeberg sclerosis revisited: a clarification of the histologic definition of Mönckeberg sclerosis. Arch Pathol Lab Med (2008) 1.25

Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS (2013) 1.23

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol (2008) 1.21

Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS (2013) 1.21

Smoking intensity and lipoprotein abnormalities in active smokers. J Clin Lipidol (2009) 1.19

A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res (2011) 1.17

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis (2003) 1.16

Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care (2011) 1.13

Association of ongoing drug and alcohol use with non-adherence to antiretroviral therapy and higher risk of AIDS and death: results from ACTG 362. AIDS Care (2011) 1.13

Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA (2012) 1.13

Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses (2011) 1.12

Metabolic disease in HIV infection. Lancet Infect Dis (2013) 1.11

Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis (2008) 1.11

Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. Am Heart J (2010) 1.10

Carotid intima-media thickness and cardiovascular disease risk prediction. J Am Coll Cardiol (2014) 1.09

Ultrasound-detected carotid plaque as a screening tool for advanced subclinical atherosclerosis. Am Heart J (2005) 1.09

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens (2011) 1.09

Calcification of the internal elastic lamina of coronary arteries. Mod Pathol (2008) 1.06

Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol (2010) 1.06

Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS (2010) 1.06

Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05

Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther (2006) 1.05

A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS (2015) 1.05

Use of carotid intima-media thickness and vascular age to modify cardiovascular risk prediction. J Am Soc Echocardiogr (2006) 1.04

Ultrasound-detected carotid plaque as a predictor of cardiovascular events. Vasc Med (2006) 1.03

Validation of a carotid intima-media thickness border detection program for use in an office setting. J Am Soc Echocardiogr (2006) 1.03

The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther (2004) 1.02

Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials (2007) 1.01

Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial. PLoS One (2013) 0.98

Longitudinal effects of a decade of aging on carotid artery stiffness: the multiethnic study of atherosclerosis. Stroke (2013) 0.97

The effects of sleep-disordered breathing on arterial stiffness are modulated by age. Sleep (2010) 0.97

Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis (2009) 0.96

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS (2010) 0.96

HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother (2011) 0.96

Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider. HIV Clin Trials (2009) 0.95

Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol (2011) 0.95

Long-term effects of smoking and smoking cessation on exercise stress testing: three-year outcomes from a randomized clinical trial. Am Heart J (2011) 0.95

The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One (2012) 0.95

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94

Increases in central aortic impedance precede alterations in arterial stiffness measures in type 1 diabetes. Diabetes Care (2007) 0.94

Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol (2008) 0.94

Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. Int J STD AIDS (2006) 0.93

Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med (2009) 0.92

Carotid intima-media thickness testing by non-sonographer clinicians: the office practice assessment of carotid atherosclerosis study. J Am Soc Echocardiogr (2007) 0.92

HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. Lipids Health Dis (2011) 0.92

Distribution and predictors of carotid intima-media thickness in young adults. Prev Cardiol (2007) 0.92

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS (2011) 0.91

Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation (2008) 0.91

Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One (2012) 0.91

Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in Acquired Immunodeficiency Syndrome. Clin Infect Dis (2002) 0.91

Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis (2007) 0.91

Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther (2013) 0.91

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther (2003) 0.90

Ultrasound detection of increased carotid intima-media thickness and carotid plaque in an office practice setting: does it affect physician behavior or patient motivation? J Am Soc Echocardiogr (2008) 0.90

Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults. Lipids Health Dis (2013) 0.89

The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis (2012) 0.89